Vimarsana
Biggest News Aggregation in the World

Page 2 - Diagnostics Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diagnostics Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diagnostics Division Today - Breaking & Trending Today

Avacta : Results for the Year Ended 31 December 2023 - Vimarsana News

Avacta : Results for the Year Ended 31 December 2023

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS NO. 596/2014 AS IT FORMS...

Avacta : Preliminary Results for the Year Ended 31 December 2023 - Vimarsana News

Avacta : Preliminary Results for the Year Ended 31 December 2023

Avacta appoints new Chief Executive Officer Christina Coughlin, MD PhD Clinical proof-of-concept demonstrated for Avacta's lead programme AVA6000 and proof-of-mechanism for the...

Novartis : Q1 2024 impact and sustainability update - Vimarsana News

Novartis : Q1 2024 impact and sustainability update

Content Click below to navigate through the document Welcome Novartis proposal for the...

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 - Vimarsana News

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

Group sales grew by 2%1 at constant exchange rates , driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there...

Madelaine Sumera Joins Mobilize Vision as SVP of Public Sector - Vimarsana News

Madelaine Sumera Joins Mobilize Vision as SVP of Public Sector

Looking for the latest Government Contracting News? Read about Madelaine Sumera Joins Mobilize Vision as SVP of Public Sector.